Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc

被引:5
|
作者
Latinovic, Olga [1 ,2 ]
Schneider, Kate [1 ,2 ]
Szmacinski, Henryk [3 ]
Lakowicz, Joseph R. [3 ]
Heredia, Alonso [1 ,4 ]
Redfield, Robert R. [1 ,4 ]
机构
[1] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA
[3] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA
[4] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA
关键词
HIV-1; CCR5; antagonist; Maraviroc; Fusion protein; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1; CHEMOKINE; TYPE-1; EXPRESSION; ENTRY; ANTIBODY; CELLS; CD4; INFECTIONS;
D O I
10.1016/j.antiviral.2014.10.006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The CCR5 chemokine receptor is crucial for human immunodeficiency virus type 1 (HIV-1) infection, acting as the principal coreceptor for HIV-1 entry and transmission and is thus an attractive target for antiviral therapy. Studies have suggested that CCR5 surface density and its conformational changes subsequent to virion engagement are rate limiting for entry, and consequently, infection. Not all CCR5 antibodies inhibit HIV-1 infection, suggesting a need for more potent reagents. Here we evaluated full length single chain (FLSC) IgG1, a novel IgG-CD4-gp12(BAL) fusion protein with several characteristics that make it an attractive candidate for treatment of HIV-1 infections, including bivalency and a potentially increased serum half-life over FLSC, the parental molecule. FLSC IgG1 binds two domains on CCR5, the N-terminus and the second extracellular loop, lowering the levels of available CCR5 viral attachment sites. Furthermore, FLSC IgG1 synergizes with Maraviroc (MVC), the only licensed CCR5 antagonist. In this study, we used both microscopy and functional assays to address the mechanistic aspects of the interactions of FLSC IgG1 and MVC in the context of CCR5 conformational changes and viral infection. We used a novel stochastic optical reconstruction microscopy (STORM), based on high resolution localization of photoswitchable dyes to visualize direct contacts between FLSC IgG1 and CCR5. We compared viral entry inhibition by FLSC IgG1 with that of other CCR5 blockers and showed FLSC IgG1 to be the most potent. We also showed that lower CCR5 surface densities in HIV-1 infected primary cells result in lower FLSC IgG1 EC50 values. In addition, CCR5 binding by FLSC IgG1, but not CCR5 Ab 2D7, was significantly increased when cells were treated with MVC, suggesting MVC allosterically increases exposure of the FLSC IgG1 binding site. These data have implications for future antiviral therapy development. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:80 / 90
页数:11
相关论文
共 50 条
  • [31] INHIBITION OF HCV REPLICATION BY CCR5 BLOCKADE WITH CENICRIVIROC AND MARAVIROC
    Sherman, K. E.
    Kong, L.
    Blackard, J. T.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S684 - S684
  • [32] CCR5 binding properties of a CCR5 small-molecule inhibitor with high antiviral potency against a maraviroc-resistant HIV-1 strain
    Jekle, A.
    Kondru, R.
    Ji, C.
    Chuang, K-T
    Swinney, D. C.
    Rotstein, D.
    Sankuratri, S.
    Cammack, N.
    Heilek, G.
    ANTIVIRAL THERAPY, 2007, 12 : S13 - S13
  • [33] Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients
    Soulie, Cathia
    Malet, Isabelle
    Lambert-Niclot, Sidonie
    Tubiana, Roland
    Thevenin, Monique
    Simon, Anne
    Murphy, Robert
    Katlama, Christine
    Calvez, Vincent
    Marcelin, Anne-Genevieve
    AIDS, 2008, 22 (16) : 2212 - 2214
  • [34] Blocking CCR5
    Chen I.
    Nature Structural & Molecular Biology, 2013, 20 (10) : 1145 - 1145
  • [35] Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay
    van der Ryst, Elna
    Heera, Jayvant
    Demarest, James
    Knirsch, Charles
    COMPANION DIAGNOSTICS: FROM BIOMARKER IDENTIFICATION TO MARKET ENTRY, 2015, 1346 : 7 - 17
  • [36] On the dimerization of CCR5
    Lemay, J
    Marullo, S
    Jockers, R
    Alizon, M
    Brelot, A
    NATURE IMMUNOLOGY, 2005, 6 (06) : 535 - 535
  • [37] On the dimerization of CCR5
    Julie Lemay
    Stefano Marullo
    Ralf Jockers
    Marc Alizon
    Anne Brelot
    Nature Immunology, 2005, 6 : 535 - 535
  • [38] Comparative Docking Study of Anibamine as the First Natural Product CCR5 Antagonist in CCR5 Homology Models
    Li, Guo
    Haney, Kendra M.
    Kellogg, Glen E.
    Zhang, Yan
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2009, 49 (01) : 120 - 132
  • [39] Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5
    Ogilvie, P
    Bardi, G
    Clark-Lewis, I
    Baggiolini, M
    Uguccioni, M
    BLOOD, 2001, 97 (07) : 1920 - 1924
  • [40] CCR5 gene editing - Revisiting pros and cons of CCR5 absence
    Ellwanger, Joel Henrique
    Kaminski, Valeria de Lima
    Bogo Chies, Jose Artur
    INFECTION GENETICS AND EVOLUTION, 2019, 68 : 218 - 220